Clinical Trials Logo

Filter by:
NCT ID: NCT00847028 Active, not recruiting - Pain Clinical Trials

Oral Glucose Solution as Pain Relief in Newborns: Results of a Clinical Trial

Start date: November 2007
Phase: N/A
Study type: Interventional

This study investigates which concentration of glucose is most effective in reducing pain for venipuncture in the newborn.

NCT ID: NCT00845117 Active, not recruiting - Clinical trials for Limbal Stem Cell Deficiency

Cultivated Stem Cell Transplantation for the Treatment of Limbal Stem Cell Deficiency

LECT
Start date: July 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether cultivated stem cell transplantation is effective for the treatment of patients wtih corneal stem cell deficiency.

NCT ID: NCT00840944 Active, not recruiting - Clinical trials for Idiopathic Short Stature

A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height

ZomaTrip
Start date: January 2008
Phase: Phase 4
Study type: Interventional

Estrogens are responsible for the disappearance of growth cartilage in the long bones at the end of the pubertal growth spurt both in boys and in girls. It is therefore hypothesized that stopping pubertal development and hence estrogen production, will prolong and increase the pubertal growth spurt, especially when growth hormone is given concommitantly. Boys in early puberty, with a bone age between 11 and 13 years and a predicted adult height below 163 cm or girls in early puberty with a bone age between 10 and 12 years and a predicted height under 151 cm will be treated with triptorelin 3.75 mg and Zomacton growth hormone for 4 years.

NCT ID: NCT00829192 Active, not recruiting - Clinical trials for Carcinoma, Squamous Cell

Phase II AK Study in Organ Transplant Patients

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether afamelanotide (CUV1647) is effective in reducing the number of actinic keratoses and squamous cell carcinomas developing in immune compromised organ transplant recipients, who are at particularly high risk, over a 24 month test period. The number of lesions formed on the head, hands and forarms will be monitored over this 24 month test period.

NCT ID: NCT00812799 Active, not recruiting - Clinical trials for Allergic Rhinoconjunctivitis

A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis

Start date: December 2008
Phase: Phase 3
Study type: Interventional

This study will be performed to determine the long-term efficacy of 19.000 BU Oralgen grass pollen administered daily in patients with grass pollen related allergic rhinoconjunctivitis.

NCT ID: NCT00809575 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes

PROMYS
Start date: October 2, 2008
Phase:
Study type: Observational

RATIONALE: Gathering information about quality of life, fatigue, and other symptoms from patients with myelodysplastic syndromes may help doctors learn more about the disease and may help plan treatment. PURPOSE: This clinical trial is studying quality of life and symptoms in patients with newly diagnosed myelodysplastic syndromes.

NCT ID: NCT00777582 Active, not recruiting - Solid Tumors Clinical Trials

Phase I Comparative Bioavailability Study

Start date: October 27, 2008
Phase: Phase 1
Study type: Interventional

The purpose of this phase I randomised cross over study is to determine and compare the bioavailability of two different oral formulations of AZD2281 in advanced solid tumour cancer patients

NCT ID: NCT00777153 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma

REGAL
Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents. Cediranib is a new drug that has not yet been approved for this disease. This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo ("inactive substance") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.

NCT ID: NCT00771888 Active, not recruiting - Liver Diseases Clinical Trials

Open-Label Extension of LOCKCYST Trial

LOCKCYST-ext
Start date: April 2008
Phase: Phase 2/Phase 3
Study type: Interventional

Positive data originating from two polycystic liver patients treated with somatostatin analogues, showed a volume reduction of 38.3% and 14.9%. These two patients had complicated polycystic livers and no other therapeutic options were available. Patients who participated in LOCKCYST trial are able to benefit from active treatment. Participants will be actively treated for 24 weeks.

NCT ID: NCT00759382 Active, not recruiting - Clinical trials for Non Small Cell Lung Carcinoma

Prognostic Role of Primary Non Small Cell Lung Carcinoma Standardized F18-FDG Uptake Values (SUV and TLG) Measured With F18-fluorodeoxyglucose Positron Emission Tomography (F18-FDG-PET): a Non Interventional Study.

Start date: July 2008
Phase:
Study type: Observational

The primary aim of this non interventional study is to assess the independent prognostic role on overall survival of primary tumour 18F-FDG uptake value (SUVmax) measured on 18fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in patients with non-metastatic non-small cell lung cancers treated with curative intent, taking into account the other conventional prognostic factors (performance status, age, sex, disease stage).